Lilly’s Broader 2026 Deal Spree Spans CAR-T, ADCs and Now JAK Inhibitors

Eli Lilly is turning 2026 into one of the most aggressive business-development years in its recent history, using acquisitions to expand beyond its established commercial franchises and build positions across next-generation oncology, cell therapy, genetic medicine and targeted small molecules.

The strategy has become particularly visible through a series of transactions involving in-vivo CAR-T, antibody-drug conjugates (ADCs) and JAK inhibitors. Rather than relying on one therapeutic technology, Lilly appears to be assembling a diversified pipeline of platforms that could produce growth beyond its existing portfolio.

The breadth of these deals is important. Lilly has moved from acquiring technologies that could engineer immune cells inside the patient to pursuing targeted cancer therapies and next-generation kinase inhibitors.

CAR-T Becomes a Major Part of Lilly’s Strategy

One of the biggest moves came in April, when Lilly agreed to acquire Kelonia Therapeutics for up to $7 billion, including $3.25 billion upfront and up to another $3.75 billion tied to milestones.

Kelonia's technology is focused on in-vivo CAR-T therapy, an approach designed to generate CAR-T cells directly inside a patient's body rather than extracting immune cells, modifying them in a manufacturing facility and reinfusing them.

The company's lead program, KLN-1010, uses a lentiviral-based gene-delivery system to selectively enter T cells and program them to become CAR-T cells. At the time of the deal, the program was being studied in Phase 1 for relapsed or refractory multiple myeloma.

This is strategically significant because conventional CAR-T therapy can involve complex manufacturing, logistics and treatment infrastructure. An effective in-vivo approach could potentially simplify the process and broaden access to cell therapy.

Lilly Had Already Bet on In-Vivo CAR-T

The Kelonia acquisition was not an isolated bet.

Earlier in 2026, Lilly agreed to acquire Orna Therapeutics, adding an in-vivo CAR-T platform based on engineered circular RNA and lipid nanoparticles. Orna's lead program, ORN-252, targets CD19 and was being developed for B-cell-driven autoimmune diseases.

Taken together, the Orna and Kelonia transactions show Lilly building exposure to different approaches for creating therapeutic immune cells inside the body.

The company is therefore not simply buying a single CAR-T asset. It is accumulating platform technologies that could potentially be applied across multiple diseases.

ADCs Add Another Layer to the Oncology Strategy

Lilly has simultaneously been strengthening its position in antibody-drug conjugates.

In May, Lilly committed up to $300 million to acquire CrossBridge Bio, a company working in the emerging field of dual-payload ADCs. These therapies are designed to attach two different therapeutic payloads to an antibody, potentially allowing cancer cells to be attacked through complementary mechanisms.

Lilly's broader oncology activity also includes an investigational Nectin-4 ADC, with early clinical data presented at the 2026 American Society of Clinical Oncology meeting.

The combination of ADC development and CAR-T investment gives Lilly exposure to two very different approaches to cancer treatment.

CAR-T attempts to harness the patient's immune system, while ADCs use targeted antibodies to deliver potent drugs directly toward cancer cells.

Now Lilly Is Moving Deeper Into JAK Inhibitors

The next important addition came through Ajax Therapeutics.

Lilly agreed in April to acquire Ajax and its lead program, AJ1-11095, a once-daily oral Type II JAK2 inhibitor being evaluated for myelofibrosis and polycythemia vera.

The significance of the asset lies in its mechanism.

Existing approved JAK2 inhibitors for myeloproliferative neoplasms primarily bind the Type I conformation of JAK2. Ajax's approach instead targets the Type II conformation, with the goal of achieving deeper and more durable disease control.

The acquisition gives Lilly another potential route into blood cancers, complementing its growing cell-therapy and oncology platform investments.

The Deals Are Connected by a Common Theme

At first glance, CAR-T, ADCs and JAK inhibitors appear to be unrelated technologies.

Strategically, however, they share an important characteristic: they target areas where improvements in precision, durability or treatment delivery could create significant clinical and commercial value.

Lilly's 2026 transactions suggest three priorities:

1. Build platforms rather than only individual drugs

The Kelonia and Orna deals give Lilly technologies that could potentially generate multiple future programs rather than a single commercial product.

2. Strengthen oncology and immunology

The company's investments span multiple forms of cancer and immune-mediated disease, creating opportunities across large and specialized patient populations.

3. Acquire innovation before late-stage commercialization

Several of the acquired assets were still in relatively early clinical development. This gives Lilly greater control over development strategy but also exposes the company to substantial clinical risk.

The Financial Commitment Is Significant

Lilly's acquisition activity is not occurring on a small scale.

Its June 2026 regulatory filing reported $2.8 billion in acquired in-process research and development charges during the second quarter alone, including $1.233 billion associated with Orna and $909 million associated with Ajax.

The same filing shows how quickly the company's balance sheet is absorbing these transactions. Lilly reported $54.9 billion in total debt at June 30, 2026, up from $42.5 billion at the end of 2025.

This does not necessarily indicate financial stress, but it demonstrates the scale of Lilly's capital commitment to pipeline expansion.

The company is effectively using its financial strength to purchase future growth opportunities before those technologies reach commercial maturity.

Lilly Is Also Diversifying Beyond Oncology

The deal spree extends beyond the three areas highlighted by the latest transactions.

In May, Lilly announced acquisitions of Curevo, LimmaTech Biologics and Vaccine Company to expand its infectious-disease portfolio.

In July, the company agreed to acquire AtaiBeckley for approximately $2.8 billion upfront, plus a potential additional $1 billion through a contingent value right, expanding Lilly's neuroscience pipeline into treatment-resistant depression and related conditions.

This broader activity suggests that Lilly's 2026 strategy is not simply an oncology acquisition campaign. It is a wider effort to build multiple future growth engines.

Why Lilly Is Buying So Aggressively

One explanation is the changing economics of pharmaceutical innovation.

Large pharmaceutical companies increasingly face pressure to replace revenue as older products mature, while breakthrough technologies are often developed first inside smaller biotechnology companies.

Acquiring these companies allows Lilly to obtain technologies without having to build every platform internally from scratch.

The strategy also spreads risk.

Instead of betting billions on one late-stage drug, Lilly is assembling a portfolio across:

• In-vivo CAR-T

• ADC technology

• JAK2 inhibition

• Genetic medicine

• Infectious disease

• Neuroscience

• Immunology

Only a portion of these programs will ultimately become successful commercial products. The objective is therefore to create enough potential winners to offset inevitable clinical failures.

The Bigger Question: Can Lilly Convert Platforms Into Products?

The size of Lilly's deal activity makes one question increasingly important: how efficiently can the company turn these acquisitions into approved medicines?

Buying promising technology is only the first step.

CAR-T platforms must demonstrate safety, durability and scalable manufacturing or delivery. ADC programs must show meaningful efficacy while maintaining acceptable toxicity. JAK inhibitors must demonstrate differentiation against established therapies.

The fact that several acquired programs are still in early clinical development means Lilly could be waiting years before their commercial potential becomes clear.

This creates a classic pharmaceutical trade-off: paying a premium today to secure potentially transformative technologies before competitors do, while accepting substantial development risk.

Conclusion

Lilly's 2026 deal spree reveals a pharmaceutical company trying to build its next generation of growth well ahead of commercial need.

The acquisitions of Orna and Kelonia give Lilly significant exposure to in-vivo CAR-T and next-generation cell engineering. The CrossBridge transaction adds exposure to dual-payload ADC technology, while Ajax brings a potentially differentiated JAK2 inhibitor into the company's oncology pipeline.

What makes the strategy notable is not simply the amount of money Lilly is spending. It is the diversity of technologies being assembled.

Lilly is effectively building a portfolio around the next wave of pharmaceutical innovation—programmable immune cells, targeted drug delivery and precision molecular therapies.

The success of this strategy will ultimately depend not on how many companies Lilly acquires, but on how many of these early-stage technologies can be transformed into durable, differentiated medicines.